melatonin has been researched along with Cardiomegaly in 13 studies
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Emerging evidence suggests pleiotropic roles of melatonin in cardiac disease; however, the effects of melatonin on physiological vs pathological cardiac hypertrophy remain unknown." | 7.91 | Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling. ( Gao, L; Gao, Y; Ji, Q; Lan, F; Pu, J; Sheng, X; Su, Y; Tong, R; Wu, F; Xu, L; Yan, Y; Ying, X; Yuan, A; Zhao, Y, 2019) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 7.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 7.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 5.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 5.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "Heart failure patients have elevated arginine vasopressin (AVP) levels, which are involved in inducing peripheral vasoconstriction and cardiac hypertrophy." | 4.12 | Melatonin alleviates arginine vasopressin-induced cardiomyocyte apoptosis via increasing Mst1-Nrf2 pathway activity to reduce oxidative stress. ( Chen, S; Du, GQ; Fu, S; Li, H; Li, Y; Sun, P; Tian, J; Wang, C, 2022) |
| " Emerging evidence suggests pleiotropic roles of melatonin in cardiac disease; however, the effects of melatonin on physiological vs pathological cardiac hypertrophy remain unknown." | 3.91 | Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling. ( Gao, L; Gao, Y; Ji, Q; Lan, F; Pu, J; Sheng, X; Su, Y; Tong, R; Wu, F; Xu, L; Yan, Y; Ying, X; Yuan, A; Zhao, Y, 2019) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 3.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 3.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 1.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 1.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "Melatonin treatment significantly mitigated the calcium handling in the hypoxic rats by preserving SERCA expression." | 1.35 | Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. ( Fung, ML; Hung, MW; Yeung, HM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Li, Y | 2 |
| Fu, S | 1 |
| Wang, C | 1 |
| Sun, P | 1 |
| Li, H | 1 |
| Tian, J | 1 |
| Du, GQ | 1 |
| Zhao, X | 1 |
| Wang, X | 1 |
| Wang, J | 1 |
| Yuan, J | 1 |
| Zhang, J | 1 |
| Zhu, X | 1 |
| Lei, C | 1 |
| Yang, Q | 1 |
| Wang, B | 1 |
| Cao, F | 1 |
| Liu, L | 1 |
| Xu, CN | 1 |
| Kong, LH | 1 |
| Ding, P | 1 |
| Liu, Y | 1 |
| Fan, ZG | 1 |
| Gao, EH | 1 |
| Yang, J | 2 |
| Yang, LF | 1 |
| Yang, Y | 3 |
| Du, J | 1 |
| Xu, R | 1 |
| Shen, Y | 1 |
| Yang, D | 1 |
| Hu, H | 1 |
| Pei, H | 1 |
| Zhai, M | 1 |
| Liu, Z | 1 |
| Zhang, B | 1 |
| Jing, L | 1 |
| Li, B | 1 |
| Li, K | 1 |
| Chen, X | 1 |
| Zhang, M | 1 |
| Yu, B | 1 |
| Ren, K | 1 |
| Yi, W | 1 |
| Liu, J | 1 |
| Yi, D | 1 |
| Liang, H | 1 |
| Jin, Z | 1 |
| Reiter, RJ | 2 |
| Duan, W | 1 |
| Yu, S | 1 |
| Ali, T | 1 |
| Mushtaq, I | 1 |
| Maryam, S | 1 |
| Farhan, A | 1 |
| Saba, K | 1 |
| Jan, MI | 1 |
| Sultan, A | 1 |
| Anees, M | 1 |
| Duygu, B | 1 |
| Hamera, S | 1 |
| Tabassum, S | 1 |
| Javed, Q | 1 |
| da Costa Martins, PA | 1 |
| Murtaza, I | 1 |
| Xu, L | 1 |
| Su, Y | 1 |
| Zhao, Y | 1 |
| Sheng, X | 1 |
| Tong, R | 1 |
| Ying, X | 1 |
| Gao, L | 1 |
| Ji, Q | 1 |
| Gao, Y | 1 |
| Yan, Y | 1 |
| Yuan, A | 1 |
| Wu, F | 1 |
| Lan, F | 1 |
| Pu, J | 1 |
| Simko, F | 2 |
| Paulis, L | 1 |
| Bednarova, KR | 1 |
| Krajcirovicova, K | 1 |
| Hrenak, J | 1 |
| Celec, P | 1 |
| Kamodyova, N | 1 |
| Gajdosechova, L | 1 |
| Zorad, S | 1 |
| Adamcova, M | 1 |
| Lu, Q | 1 |
| Yi, X | 1 |
| Cheng, X | 1 |
| Sun, X | 1 |
| Yang, X | 1 |
| Xie, S | 1 |
| Deng, Y | 1 |
| Pan, YY | 1 |
| Wang, ZH | 1 |
| Ren, J | 1 |
| Guo, XL | 1 |
| Yuan, X | 1 |
| Shang, J | 1 |
| Liu, HG | 1 |
| Manchester, LC | 1 |
| Fuentes-Broto, L | 1 |
| Tan, DX | 1 |
| Yeung, HM | 1 |
| Hung, MW | 1 |
| Fung, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intervention Effect Of Melatonin On The Risk Of Cardiovascular Events And Malignant Tumors In The Elderly: A Prospective, Randomized Parallel Controlled Study Based On Large Cohorts[NCT04631341] | 10,000 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for melatonin and Cardiomegaly
| Article | Year |
|---|---|
Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin.
Topics: Animals; Cardiomegaly; Hypertension; Melatonin; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2010 |
12 other studies available for melatonin and Cardiomegaly
| Article | Year |
|---|---|
Melatonin alleviates arginine vasopressin-induced cardiomyocyte apoptosis via increasing Mst1-Nrf2 pathway activity to reduce oxidative stress.
Topics: Apoptosis; Arginine Vasopressin; Cardiomegaly; Humans; Melatonin; Myocytes, Cardiac; NF-E2-Related F | 2022 |
A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Drug Delivery Systems; Ferrosoferric Oxide; Fibrosis; | 2020 |
Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cardiomegaly; Disease Models, Animal; Fi | 2020 |
Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.
Topics: Angiotensin II; Animals; Antioxidants; Calcium-Binding Proteins; Cardiomegaly; Disease Models, Anima | 2020 |
Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.
Topics: Angiotensin II; Animals; Antioxidants; Cardiomegaly; Disease Models, Animal; Drug Evaluation, Precli | 2017 |
Interplay of N acetyl cysteine and melatonin in regulating oxidative stress-induced cardiac hypertrophic factors and microRNAs.
Topics: Acetylcysteine; Animals; Cardiomegaly; Cell Line; Disease Models, Animal; Free Radical Scavengers; G | 2019 |
Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Melatonin; Mice; Mice, Mutant Strains; Nuclear Recept | 2019 |
Antifibrotic effect of melatonin--perspective protection in hypertensive heart disease.
Topics: Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Melatonin; Myocardium | 2013 |
Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Male; Melatonin; Rats; Rats, Wistar | 2014 |
Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.
Topics: Animals; Calcineurin; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Car | 2015 |
Melatonin protects against chronic intermittent hypoxia-induced cardiac hypertrophy by modulating autophagy through the 5' adenosine monophosphate-activated protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Cardiotonic Agents; Cell Line; Chro | 2015 |
Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats.
Topics: Animals; Antioxidants; Blotting, Western; Calcium; Cardiomegaly; Cells, Cultured; Hematocrit; Homeos | 2008 |